Axial involvement is present in approximately 25% of patients with PsA, with enthesitis, inflammatory bowel disease, and ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

The following is a summary of “Health-related quality of life significantly improved in obese patients with psoriatic arthritis one year after a structured weight loss intervention,” published in the ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and ...

The following is a summary of “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...